ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer patients undergoing therapy with trastuzumab

Circulating HER2 extracellular domain (HER2 ECD) levels were proposed as a surrogate for HER2 tissue expression to monitor breast cancer patients for early relapse or responses to standard or HER2-targeted therapies, such as the monoclonal antibody (mAb) trastuzumab. Currently, available commercial...

Descripción completa

Detalles Bibliográficos
Autores principales: Agnolon, Valentina, Contato, Anna, Meneghello, Anna, Tagliabue, Elda, Toffoli, Giuseppe, Gion, Massimo, Polo, Federico, Fabricio, Aline S. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033231/
https://www.ncbi.nlm.nih.gov/pubmed/32080226
http://dx.doi.org/10.1038/s41598-020-59630-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033231/
https://www.ncbi.nlm.nih.gov/pubmed/32080226
http://dx.doi.org/10.1038/s41598-020-59630-y

Ejemplares similares